Spark Therapeutics Inc 's ability to collect its outstanding accounts receivable from its corporate clients, has improved in the third quarter 2019 to a ratio of 1.71, above the company average. This is a clear sign of healthy business climate in the Biotechnology & Pharmaceuticals industry and improving liquidity at their respective customers, during the third quarter 2019. Average receivable collection period, for the Spark Therapeutics Inc in Sep 30 2019 quarter, has decreased to 213 days, compared to 221 days, in the Jun 30 2019 quarter.

If we take a look into Healthcare sector 481 other companies have achieved higher receivables turnover ratio. While receivables turnover ratio total ranking has improved thus far to 3531, from overall ranking in the second quarter 2019 at 3707.

What is Receivable Turnover Ratio?
What is Spark Therapeutics Inc Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

ONCE Receivables Turnover Ratio	(Sep 30 2019) III. Quarter	(Jun 30 2019) II. Quarter	(Mar 31 2019) I. Quarter	(Dec 31 2018) IV. Quarter	(Sep 30 2018) III. Quarter
Y / Y Receivable Change	162.71 %	137.22 %	-3.36 %	499.38 %	125.1 %
Y / Y Revenue Change	109.65 %	-46.38 %	32.5 %	77.6 %	463.65 %
Receivable Turnover Ratio (TTM)	1.71	1.65	2.62	2.41	3.48
ONCE's Total Ranking	# 3531	# 3707	# 3707	# 2066	# 3707
Accounts Receivable average collection period days	213	222	139	151	105
Seq. Receivable Change	-40.74 %	192.52 %	-56.8 %	250.84 %	-46.49 %
Seq. Revenue Change	66.24 %	-34.99 %	57.87 %	22.88 %	-57.49 %

Receivable Turnover Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 41
Healthcare Sector	# 482
Overall Market	# 3531

Receivable Turnover Ratio Statistics
High	Average	Low
0.09	0.07	0.03
(Sep 30 2019)		(Dec 31 2017)

ONCE Company Profile • Back to ONCE Efficiency Comparisons • Compare ONCE Receivables Turnover Ratio to its Competitors

Financial Statements
Spark Therapeutics Inc 's Accounts Receivable	$ 35 Millions	Visit ONCE's Balance sheet
Spark Therapeutics Inc 's Sales TTM	$ 70 Millions	Visit ONCE's Income Statement
Sources of ONCE's Revenues		Visit ONCE's Sales by Geography

Other Accounts Receivable Turnover Ratios
Biotechnology & Pharmaceuticals Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
ONCE's Receivable Turnover Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
ONCE's Growth Rates	ONCE's Roa	ONCE's Inventory Turnover Ratio	ONCE's Dividend Comparisons
ONCE's Profitability Ratios	ONCE's Roi	ONCE's Asset Turnover Ratio	ONCE's Dividend Growth
ONCE's Valuation Ratios	ONCE's Roe	ONCE's Financial Strength Ratios	ONCE's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Sep 30 2019, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Sep 30 2019	Receivable at quarter ending Sep 30 2019
Strongbridge Biopharma plc	5.41	$ 20.620 Millions	$ 3.812 Millions
Allergan plc	5.41	$ 15,817.600 Millions	$ 2,924.475 Millions
Vivosim Labs Inc	5.40	$ 3.357 Millions	$ 0.621 Millions
Orthopediatrics Corp	5.40	$ 68.168 Millions	$ 12.630 Millions
Cambrex Corp	5.38	$ 619.201 Millions	$ 115.131 Millions
Resmed Inc	5.37	$ 2,699.349 Millions	$ 502.729 Millions
Integra Lifesciences Holdings Corp	5.37	$ 1,505.745 Millions	$ 280.609 Millions
Nevro Corp	5.34	$ 383.825 Millions	$ 71.890 Millions
Orasure Technologies Inc	5.31	$ 155.183 Millions	$ 29.226 Millions
Assembly Biosciences Inc	5.30	$ 14.931 Millions	$ 2.816 Millions
Tetraphase Pharmaceuticals Inc	5.30	$ 9.969 Millions	$ 1.883 Millions
Conmed Corporation	5.28	$ 932.675 Millions	$ 176.517 Millions
Vericel Corporation	5.27	$ 109.795 Millions	$ 20.818 Millions
Msa Safety Inc	5.26	$ 1,388.510 Millions	$ 264.056 Millions
Anika Therapeutics Inc	5.20	$ 111.794 Millions	$ 21.501 Millions
Alnylam Pharmaceuticals Inc	5.15	$ 169.102 Millions	$ 32.852 Millions
Neogen Corporation	5.14	$ 415.984 Millions	$ 80.997 Millions
Globus Medical Inc	5.14	$ 769.639 Millions	$ 149.874 Millions
Medtronic Plc	5.13	$ 30,891.000 Millions	$ 6,022.000 Millions
Apollo Endosurgery inc	5.12	$ 53.906 Millions	$ 10.524 Millions
Pressure Biosciences Inc	5.10	$ 2.217 Millions	$ 0.435 Millions
Guardant Health Inc	5.09	$ 184.351 Millions	$ 36.183 Millions
Thermogenesis Holdings Inc	5.07	$ 14.013 Millions	$ 2.766 Millions
Aspira Women s Health inc	5.06	$ 4.152 Millions	$ 0.820 Millions
Yunhong Green Cti Ltd	5.03	$ 47.374 Millions	$ 9.427 Millions
Iridex Corp	5.02	$ 43.152 Millions	$ 8.592 Millions
Chembio Diagnostics Inc	5.02	$ 35.384 Millions	$ 7.051 Millions
Enveric Biosciences Inc	5.00	$ 41.133 Millions	$ 8.231 Millions
Charles River Laboratories International inc	4.97	$ 2,531.618 Millions	$ 509.243 Millions
Healthcare Services Group Inc	4.95	$ 1,722.183 Millions	$ 347.841 Millions

Date modified: 2026-06-22T16:30:23+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.